MAM
Rotomac appoints Ignite Mudra as branding and creative partner
MUMBAI: Rotomac Pens has appointed Ignite Mudra to handle branding and creative duties for its corporate and writing instruments brands.
The agency’s approach on how will they get a brand agnostic consumer show discernment towards brands has won them the business.
Ignite Mudra head Sudarshan Banerjee said that in this market most of the purchases are ‘brand agnostic’ since the consumer doesn’t really pay too much attention to the brand of pen he uses.
Sudarshan Banerjee said, “The brand is a leader in its business and has a strong residual image in the consumer’s mind. We’re sure that there’ll be some truly exciting work on Rotomac very soon.”
Rotomac president Rahul Kothari said, “The last decade has been truly exciting with the entry of many players and competition heating up in a big way. The market itself is undergoing a tectonic shift with increasing literacy and evolving tastes of the Indian consumer. Our interactions with Ignite Mudra have cemented our belief that they are the ideal partner to drive exponential growth for brand Rotomac in the coming years.”
Ignite Mudra, has built brands for entrepreneurial ventures in the past three decades, such as Reliance (Vimal), Rasna, Dhara, Paras Pharmaceuticals (Itchguard, Dermicool, Moov, Krack, Recova, Livon), Electrotherm (YObykes), and Zydus Cadila (Nutralite, Sugar Free, Everyuth).
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
